Scailyte ready for market growth

Please login or
register
30.08.2021
Scailyte Team
Scailyte’s artificial intelligence platform for biomarker discovery from single-cell and clinical data enables precision diagnostics in oncology, immunology and women’s health. Following the successful completion of the Innosuisse coaching program, Scailyte has obtained the Innosuisse certificate, attesting to the company’s readiness for growth.

ScaiVision, Scailyte’s proprietary biomarker discovery platform uses machine learning algorithms to identify predictive patterns in high-dimensional single-cell data. By analyzing millions of individual cells with an unbiased approach, the startup can identify the precise molecular profiles (biomarkers) of specific cell types associated with a disease state at a high level of sensitivity.

The company’s current clinical focus lies in developing precision diagnostic applications for oncology and women’s health by identifying biomarkers that outperform the current standard of care. Scailyte has so far identified five biomarkers, with four in the advanced stages. Cutaneous T-cell lymphoma (CTCL) is the first and most advanced disease and clinically validated biomarker. CTCL is a rare and severe skin cancer with no definitive diagnostic test, resulting in delayed or misdiagnosis. The most aggressive form of CTCL is Sezary Syndrome, with a 5-year survival rate between 20–27%.

Recent discoveries include biomarkers for diagnosing endometriosis, a severe medical disorder affecting one of ten women, which is approximately 176 million women worldwide. There is curr ently no molecular diagnostic assay for identifying the disease; therefore, Scailyte will be the first to enable early diagnosis, cutting the time from seven years to a few days.

Investors, partners and supporters drive Scailyte’s success
More than 7.5 million in equity investment and additional non-dilutive grants have flown into Scailyte since incorporation in 2017, and the series A round is nearing a close. With its 15 employees, the startup founded by Peter Nestorov, Manfred Claassen, Dennis Göhlsdorf and Daniel Sonnleithner has rapidly expanded its partnership network to accelerate development. On the R&D side, Scailyte is partnering with leading research hospitals around the globe, and on the commercial side, the company is  partnering with established players in diagnostics and biotechnology industries

The Innosuisse coaching program has additionally played a vital role in the startup’s progress. During its 3.5 year term in the program, Scailyte’s team, with the support of its coach Andreas Schulze, honed their entrepreneurial skills, which encompass pitching, fundraising, business development and networking. Special Innosuisse coaches further complemented the teams’ skills with legal know-how on IP and patents. Having completed the program, Scailyte received the Innosuisse Certificate as a seal of maturity and readiness for sustainable growth.

In line with its growth, Scailyte has opened a new office in Boston and appointed a business development expert to lay the ground for its upcoming activities and partnerships in the US.

(RAN)

0Comments

More news about

Scailyte AG

Company profiles on startup.ch

Scailyte AG

rss